Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats

A. Sporková, S. Jíchová, Z. Husková, L. Kopkan, A. Nishiyama, SH. Hwang, BD. Hammock, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, HJ. Kramer, L. Cervenka,

. 2014 ; 41 (12) : 1003-1013.

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031855

Grantová podpora
NT12171 MZ0 CEP - Centrální evidence projektů

Recent studies have shown that the long-term antihypertensive action of soluble epoxide hydrolase inhibition (sEH) in angiotensin-II (AngII)-dependent hypertension might be mediated by the suppression of intrarenal AngII levels. To test this hypothesis, we examined the effects of acute (2 days) and chronic (14 days) sEH inhibition on blood pressure (BP) in transgenic rats with inducible AngII-dependent hypertension. AngII-dependent malignant hypertension was induced by 10 days' dietary administration of indole-3-carbinol (I3C), a natural xenobiotic that activates the mouse renin gene in Cyp1a1-Ren-2 transgenic rats. BP was monitored by radiotelemetry. Acute and chronic sEH inhibition was achieved using cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid, given at doses of 0.3, 3, 13, 26, 60 and 130 mg/L in drinking water. At the end of experiments, renal concentrations of epoxyeicosatrienoic acids, their inactive metabolites dihydroxyeicosatrienoic acids and AngII were measured. Acute BP-lowering effects of sEH inhibition in I3C-induced rats was associated with a marked increase in renal epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids ratio and acute natriuresis. Chronic treatment with cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced rats elicited dose-dependent persistent BP lowering associated with a significant reduction of plasma and kidney AngII levels. Our findings show that the acute BP-lowering effect of sEH inhibition in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated by a substantial increase in intrarenal epoxyeicosatrienoic acids and their natriuretic action without altering intrarenal renin-angiotensin system activity. Long-term antihypertensive action of cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated mostly by suppression of intrarenal AngII concentration.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031855
003      
CZ-PrNML
005      
20191024110156.0
007      
ta
008      
151005s2014 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1440-1681.12310 $2 doi
035    __
$a (PubMed)25224811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Sporková, Alexandra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0239945
245    10
$a Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats / $c A. Sporková, S. Jíchová, Z. Husková, L. Kopkan, A. Nishiyama, SH. Hwang, BD. Hammock, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, HJ. Kramer, L. Cervenka,
520    9_
$a Recent studies have shown that the long-term antihypertensive action of soluble epoxide hydrolase inhibition (sEH) in angiotensin-II (AngII)-dependent hypertension might be mediated by the suppression of intrarenal AngII levels. To test this hypothesis, we examined the effects of acute (2 days) and chronic (14 days) sEH inhibition on blood pressure (BP) in transgenic rats with inducible AngII-dependent hypertension. AngII-dependent malignant hypertension was induced by 10 days' dietary administration of indole-3-carbinol (I3C), a natural xenobiotic that activates the mouse renin gene in Cyp1a1-Ren-2 transgenic rats. BP was monitored by radiotelemetry. Acute and chronic sEH inhibition was achieved using cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid, given at doses of 0.3, 3, 13, 26, 60 and 130 mg/L in drinking water. At the end of experiments, renal concentrations of epoxyeicosatrienoic acids, their inactive metabolites dihydroxyeicosatrienoic acids and AngII were measured. Acute BP-lowering effects of sEH inhibition in I3C-induced rats was associated with a marked increase in renal epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids ratio and acute natriuresis. Chronic treatment with cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced rats elicited dose-dependent persistent BP lowering associated with a significant reduction of plasma and kidney AngII levels. Our findings show that the acute BP-lowering effect of sEH inhibition in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated by a substantial increase in intrarenal epoxyeicosatrienoic acids and their natriuretic action without altering intrarenal renin-angiotensin system activity. Long-term antihypertensive action of cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated mostly by suppression of intrarenal AngII concentration.
650    _2
$a angiotensin II $x metabolismus $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $7 D000959
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a cytochrom P-450 CYP1A1 $x metabolismus $7 D019363
650    _2
$a epoxid hydrolasy $x antagonisté a inhibitory $x metabolismus $7 D004851
650    _2
$a hypertenze $x farmakoterapie $x metabolismus $7 D006973
650    _2
$a indoly $x metabolismus $7 D007211
650    _2
$a ledviny $x účinky léků $x metabolismus $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a natriuréza $x účinky léků $7 D009318
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani inbrední F344 $7 D011916
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renin $x metabolismus $7 D012083
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jíchová, Šárka $7 xx0239935
700    1_
$a Husková, Zuzana, $d 1978- $7 xx0074206
700    1_
$a Kopkan, Libor $7 xx0107287
700    1_
$a Nishiyama, Akira
700    1_
$a Hwang, Sung H
700    1_
$a Hammock, Bruce D
700    1_
$a Imig, John D
700    1_
$a Kompanowska-Jezierska, Elzbieta
700    1_
$a Sadowski, Janusz
700    1_
$a Kramer, Herbert J
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 41, č. 12 (2014), s. 1003-1013
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25224811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20191024110631 $b ABA008
999    __
$a ok $b bmc $g 1092731 $s 914981
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 41 $c 12 $d 1003-1013 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
GRA    __
$a NT12171 $p MZ0
LZP    __
$a Pubmed-20151005
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace